FDA Issues 14 Warning Letters on DMBA to Supplement Companies
The warning letters were issued about six months after researchers who found DMBA in several supplements reported that the substance hadn’t been studied in humans and was an analogue of another controversial ingredient.
FDA recently demanded that 14 companies in the natural products industry cease distribution of supplements that contain a substance known as DMBA.
FDA warned it may take additional enforcement action without further notice if the “adulterated" products aren’t immediately taken off the market.
The warning letters were issued about six months after researchers reported in the journal Drug Testing and Analysis that the substance hadn’t been studied in humans and was an analogue of another controversial ingredient that FDA has declared cannot be marketed in supplements: DMAA.